论文部分内容阅读
重症肌无力(MG)是由乙酰胆碱受体(AChR)抗体介导的细胞免疫依赖和补体参与的一种获得性自身免疫性疾病,病变主要累及神经-肌肉接头(NMJ)突触后膜上的AChR,从而导致NMJ传递障碍。目前MG的治疗手段多种多样,但迄今为止没有任何一种手段单独使用能够很好的治疗MG,且由于对自身免疫反应的抑制,药物治疗副反应很大。相信随着人类对MG发病机制的进一步了解,将会为MG患者提供新的更好的治疗办法。
Myasthenia Gravis (MG) is an acquired autoimmune disease mediated by AChR antibody-mediated cellular immune-dependent and complement-dependent pathologies that predominantly involve the neuromuscular junction (NMJ) postsynaptic membrane AChR, resulting in NMJ delivery disorders. At present, there are a variety of treatments for MG, but so far none of them has been proven to be a good treatment for MG alone. The side effects of medical treatment are substantial due to the inhibition of the autoimmune response. Believe that with the human understanding of the pathogenesis of MG, MG patients will provide new and better treatment.